Immune-related genes play an important role in malignant pleural mesothelioma prognosis. They can affect the tumor immune microenvironment and affect tumor prognosis. Immune-related genes can be used to predict the course of a disease or patient outcomes. These genes are often called a genetic prognostic signature.
Chinese surgeons recently discovered a prognostic signature for malignant pleural mesothelioma patients.
Constructing a Prognostic Signature with 5 Immune-Related Genes
Genes play an important role in the development and progression of cancers like mesothelioma. The Chinese researchers started by searching for other studies on mesothelioma prognosis and genes.
Researchers used data from the Cancer Genome Atlas to construct the prediction signature. Patients were divided into high-risk and low-risk groups. They also used this data to verify it with an external validation dataset.
A statistical two-dimensional calculating device was constructed based on the data. This device’s predictive ability was evaluated and analyzed.
Using a complex series of calculations, the team determined which genes were most important in mesothelioma prognosis. The list was narrowed to just five genes.
There were five immune-related genes used for the prognostic signature. They were INHBA, CAT, SORT1, TNFSF13B, and BIRC5.
This signature had high predictive performance. The predictive accuracy of the signature was verified by using an independent dataset.
Five Genes to Predict Mesothelioma Prognosis and Outcomes
This research developed and verified a new type of immune prognostic signature. The signature was based on five immune-related genes.
These genes can predict malignant pleural mesothelioma prognosis. Clinicians can use these genes to estimate clinical outcomes. They can monitor personalized prognosis. And they can guide clinical management of malignant pleural mesothelioma patients.
This signature can also provide new ideas for individualized treatment.
The team constructed a prognostic signature of malignant pleural mesothelioma patients. It can predict the prognosis of individual cases. Moreover, it provides a new direction for guiding individualized and accurate treatment.
Zhang, Xiangxin, Xiangdong Huang, Zhexin Wang, and Kejian Zhang. “Establishment and validation of a novel immune-related prognostic signature in malignant pleural mesothelioma.” Annals of Translational Medicine 10, no. 4 (2022). https://dx.doi.org/10.21037%2Fatm-22-527